PCN12 EFFICACY OF SECOND LINE TREATMENTS IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER (MHRPC) IS NOT DEMONSTRATED BY PUBLISHED EVIDENCE FROM NONRANDOMIZED TRIALS
Abstract
Authors
N Freemantle M Mason Mosqueda JG Jasso F Nixon S Budhia